Zynerba Pharmaceuticals (NASDAQ:ZYNE)‘s stock had its “buy” rating reissued by research analysts at LADENBURG THALM/SH SH in a research note issued on Thursday, May 30th, AnalystRatings.com reports. They presently have a $26.00 price target on the stock. LADENBURG THALM/SH SH’s price target points to a potential upside of 130.70% from the stock’s previous close.
Several other equities analysts have also commented on the stock. Roth Capital initiated coverage on shares of Zynerba Pharmaceuticals in a research report on Tuesday, April 30th. They set a “buy” rating and a $36.00 price objective for the company. ValuEngine lowered shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, March 12th. Canaccord Genuity began coverage on shares of Zynerba Pharmaceuticals in a report on Monday, April 22nd. They issued a “buy” rating and a $8.09 target price for the company.